Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk

Int J Neuropsychopharmacol. 2024 Mar 1;27(3):pyae014. doi: 10.1093/ijnp/pyae014.

Abstract

Background: The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments.

Methods: We systematically reviewed data from 5 databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data. The primary outcome was the transition to psychosis. Network meta-analyses were conducted at 3 time points (6, 12, and ≥24 months) considering both pharmacological/nutritional interventions alone and its combination with psychotherapy.

Results: Out of 11 417 identified references, 21 studies were included, comprising 1983 participants. CHR-P participants receiving omega-3 polyunsaturated fatty acids treatment were associated with a lower probability of transition compared with placebo/control at 6 months (odds ratio [OR] = 0.07, 95% confidence interval [CI] = .01 to .054), 12 months (OR = 0.14, 95% CI = .03 to .66), and ≥24 months (OR = 0.16, 95% CI = .05 to .54). Moreover, risperidone plus psychotherapy was associated with a lower likelihood of transition at 6 months compared with placebo/control plus psychotherapy, but this result was not sustained over longer durations.

Conclusion: Omega-3 polyunsaturated fatty acids helped in preventing transitions to psychosis compared with controls.

Prospero registration number: CRD42021256209.

Keywords: Clinical high risk of psychosis; network meta-analysis; omega-3 polyunsaturated fatty acids.

Publication types

  • Systematic Review
  • Meta-Analysis

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / therapeutic use
  • Fatty Acids, Omega-3* / administration & dosage
  • Fatty Acids, Omega-3* / pharmacology
  • Humans
  • Network Meta-Analysis*
  • Psychotherapy / methods
  • Psychotic Disorders* / prevention & control
  • Psychotic Disorders* / therapy

Substances

  • Fatty Acids, Omega-3
  • Antipsychotic Agents